CardioQ covered
This article was originally published in The Gray Sheet
Executive Summary
UK firm Deltex Medical's CardioQ esophageal Doppler monitor gets national coverage from CMS May 22. The agency's 1decision to cover Doppler monitoring of cardiac output for ventilated patients in the ICU and patients with a need for intra-operative fluid optimization during surgery mirrors CMS' earlier proposal to reverse its long-standing noncoverage policy for the procedure (2"The Gray Sheet" March 5, 2007, In Brief). The esophageal Doppler monitor competes with pulmonary artery catheters, providing real-time data on left ventricular blood flow. "Given the breadth of the coverage determination, between 5 and 10 million patients [in the U.S.] annually would benefit ... using CardioQ," Deltex CEO Andy Hill told "The Gray Sheet"...
You may also be interested in...
Coverage for ultrasound diagnostic
CMS 1proposes Feb. 26 to remove national non-coverage of cardiac output Doppler monitoring, noting "there is sufficient evidence to conclude that esophageal Doppler monitoring of cardiac output for ventilated patients in the ICU and operative patients with a need for intra-operative fluid optimization is reasonable and necessary." CMS was asked to reconsider its existing non-coverage policy by UK-based Deltex Medical Group, whose CardioQ esophageal Doppler monitor was cleared by FDA in 2003 (2"The Gray Sheet" Sept. 11, 2006, p. 12). Comments on the proposal are due March 28, with a final decision expected in May...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.